Showing 641 - 660 results of 1,775 for search '(( 10 ((peer decrease) OR (((a decrease) OR (mean decrease)))) ) OR ( 6 10 decrease ))*', query time: 0.15s Refine Results
  1. 641
  2. 642
  3. 643
  4. 644
  5. 645
  6. 646

    Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus by Dimitrios, Patoulias

    Published 2023
    “…They have demonstrated1 that empagliflozin treatment resulted in a significant decrease in pulse pressure (PP), mean arterial pressure (MAP) and cardiac workload, compared with placebo; at week 12, placebo-adjusted mean changes from baseline were − 2.5 mmHg for PP, − 2.2 mmHg for MAP and − 315 mmHg x beats per minute (bpm) for cardiac workload (p < 0.0001 for all). …”
    Get full text
    Get full text
    Get full text
  7. 647
  8. 648
  9. 649

    CLINICAL AND ECONOMIC IMPACT OF GENETIC AND NON-GENETIC FACTORS ON INR NORMALIZATION IN PRE-OPERATIVE MANAGEMENT OF WARFARIN PATIENTS by ELJILANY, ISLAM AHMED SAYED AHMED

    Published 2021
    “…To optimize the period of preprocedural warfarin interruption to decrease the incidence of bleeding in case of bridging and the incidence of thromboembolism in case of non-bridging, a study was conducted to determine the influence of CYP2C9, VKORC1, CYP4F2, FII, and FVII genetic polymorphisms and non-genetic factors on INR decline in a cohort of Arabs undergoing a procedure that requires warfarin interruption and developing an algorithm to tailor the duration of warfarin interruption before the procedure. …”
    Get full text
  10. 650
  11. 651
  12. 652
  13. 653
  14. 654
  15. 655
  16. 656
  17. 657
  18. 658
  19. 659
  20. 660